1. Home
  2. SNA vs RPRX Comparison

SNA vs RPRX Comparison

Compare SNA & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Snap-On Incorporated

SNA

Snap-On Incorporated

HOLD

Current Price

$369.87

Market Cap

18.3B

ML Signal

HOLD

Logo Royalty Pharma plc

RPRX

Royalty Pharma plc

HOLD

Current Price

$44.60

Market Cap

16.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNA
RPRX
Founded
1920
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.3B
16.7B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
SNA
RPRX
Price
$369.87
$44.60
Analyst Decision
Buy
Strong Buy
Analyst Count
5
4
Target Price
$361.00
$47.75
AVG Volume (30 Days)
342.2K
3.9M
Earning Date
02-05-2026
02-11-2026
Dividend Yield
2.63%
2.13%
EPS Growth
N/A
N/A
EPS
19.19
1.75
Revenue
$5,156,100,000.00
$2,349,844,000.00
Revenue This Year
N/A
$38.81
Revenue Next Year
$3.42
$2.26
P/E Ratio
$19.32
$25.18
Revenue Growth
0.93
3.70
52 Week Low
$289.81
$29.66
52 Week High
$388.96
$44.36

Technical Indicators

Market Signals
Indicator
SNA
RPRX
Relative Strength Index (RSI) 52.14 78.82
Support Level $364.01 $40.16
Resistance Level $388.96 $44.36
Average True Range (ATR) 7.89 0.66
MACD -0.36 0.38
Stochastic Oscillator 36.01 98.45

Price Performance

Historical Comparison
SNA
RPRX

About SNA Snap-On Incorporated

Snap-on is a manufacturer of premium tools, equipment, and diagnostics for professional technicians, primarily involved in the repair of passenger cars but having expanded into other industrial applications. The company's legacy business is selling hand tools through franchisee-operated mobile vans to technicians who purchase the tools at their own expense. The company also operates a commercial and industrial business that is focused on repair facilities serving other industries. The third segment, repair systems and information, targets auto OEMs and large dealerships more directly and also offers substantial diagnostic solutions to aid repairs. The company's finance arm provides financing to franchisees to run their operations, as well as underwriting end customer purchases.

About RPRX Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Share on Social Networks: